Mar 12, 2025
Obesity is the second leading cause of preventable death, associated with a range of inflammatory conditions that contribute to cardiovascular disease, diabetes, respiratory problems, mental health issues, hypertension, obstructive sleep apnea, cancer, and high cholesterol. This represents a significant public heal...
Read More...
Mar 12, 2025
With the growing global health concern regarding obesity, Novo’s WEGOVY (semaglutide) has emerged as a leading solution in the weight loss treatment market. WEGOVY is a GLP-1 receptor agonist used alongside a low-calorie diet and increased physical activity. This obesity medication is administered as a weekly subcu...
Read More...
Mar 12, 2025
Obesity is the second leading cause of preventable death and is linked to numerous inflammatory conditions, which contribute to diseases like cardiovascular disease, diabetes, respiratory issues, mental health disorders, hypertension, obstructive sleep apnea, cancer, and high cholesterol. This poses a significant p...
Read More...
Mar 12, 2025
Obesity isn't just a personal struggle; it's a worldwide epidemic affecting over 1 billion people. This alarming statistic highlights an urgent need for effective interventions, as obesity dramatically raises the risk of life-threatening conditions like type 2 diabetes, heart disease, sleep apnea, and even certain ...
Read More...
Jan 21, 2025
FDA Approves LUMAKRAS and VECTIBIX for KRAS G12C-Mutated Colorectal Cancer Amgen has secured FDA approval for LUMAKRAS (sotorasib) in combination with VECTIBIX (panitumumab) as a treatment for adults with KRAS G12C-mutated metastatic colorectal cancer (mCRC) who have previously received fluoropyrimidine-, oxalip...
Read More...
Jan 06, 2025
Eli Lilly’s blockbuster weight loss GLP-1 drug ZEPBOUND has received FDA approval to treat obstructive sleep apnea in adults with obesity, alongside diet and exercise. This marks the first FDA-approved medication for obstructive sleep apnea. The approval adds a second indication for ZEPBOUND, following its...
Read More...
Jul 03, 2024
Energy drinks have become a ubiquitous part of modern life, promising quick boosts of energy, enhanced mental alertness, and improved physical performance. These beverages are particularly popular among young adults, athletes, and professionals who often face demanding schedules and high levels of stress. However, ...
Read More...
Mar 20, 2024
Over the years, the landscape of Digestive Health Products has undergone significant evolution driven by advancements in scientific understanding, changing consumer preferences, and emerging market trends. As per the latest study by DelveInsight, the global Digestive Health Products market was valued at USD 39,345....
Read More...
Mar 12, 2024
BeiGene Receives FDA Accelerated Approval for BRUKINSA in Relapsed/Refractory Follicular Lymphoma BeiGene, Ltd., has declared that the FDA has provided accelerated approval for BRUKINSA® (zanubrutinib) to be used in treating adult patients with relapsed or refractory (R/R) follicular lymphoma (FL), when used alo...
Read More...
Jan 02, 2024
Cytokinetics Announces Positive Results From SEQUOIA-HCM, the Pivotal Phase III Clinical Trial of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy Cytokinetics, Incorporated released favorable top-line findings from the SEQUOIA-HCM trial (Safety, Efficacy, and Quantitative Understanding of Obst...
Read More...
LEQEMBI: A New Hope for Alzheimer’s Disease Patients
Feb 12, 2025
Roche’s HER2-Positive Breast Cancer Treatment Franchise
Aug 13, 2024
Newsletter/Whitepaper